Boundless Bio, Inc. filed an 8-K on August 28, 2026, announcing Amendment No. 1 to the Agreement and Plan of Merger with Serapha Bio, Inc., originally entered into on June 22, 2026. The amendment clarifies definitions related to the Company Pre-Closing Financing, establishes mechanics for converting Serapha restricted stock unit awards into Assumed RSUs covering Boundless Bio common stock adjusted by the Exchange Ratio, and permits the issuance of pre-funded warrants as merger consideration to avoid beneficial ownership limitations. Additionally, the voting standard for increasing authorized shares was changed from a majority of outstanding shares to a majority of votes properly cast. Boundless Bio operates in the biotechnology industry, focusing on developing novel therapies.

Boundless Bio, Inc. entered into a merger agreement with Serapha Bio, Inc. to undergo a reorganization, with Serapha equityholders expected to own approximately 96.31% of the combined company. The transaction includes a potential pre-closing cash dividend and a planned reverse stock split. Boundless Bio also announced a 75% workforce reduction with expected costs between $3.0 million and $5.0 million. Boundless Bio is a biotechnology company focused on developing therapeutic solutions for genetic diseases.